Income Statement BlossomHill Therapeutics, Inc.

Stocks

End-of-day quote Nasdaq Other stock markets 07/08/2026			5-day change	1st Jan Change
16.00 ^USD	0.00%		0.00%	-

08-07	BlossomHill Therapeutics Shares Fall in Nasdaq Debut	MT
08-07	BlossomHill Therapeutics Prices Upsized Nasdaq IPO	MT

7e03faae35a928f51da00aae4.OP4cNyxpD2D7Due2TpRp-SjCaBw1w90O_ca8tlR_LbI.SqYqU30FXgSLY43EIMQKqhiUI18NkJJkv_DOhAQmRMhT00R8fFtjOsh-kA

Published financial data: BLOSSOMHILL THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2024	2025
Selling General & Admin Expenses, Total	4.59M	7.89M
R&D Expenses	31.81M	56.14M
Other Operating Expenses, Total	36.4M	64.02M
Operating Income	-36.4M	-64.02M
Interest And Investment Income	5.71M	3.48M
Net Interest Expenses	5.71M	3.48M
Currency Exchange Gains (Loss)	-	-11K
EBT, Excl. Unusual Items	-30.7M	-60.56M
EBT, Incl. Unusual Items	-30.7M	-60.56M
Earnings From Continuing Operations	-30.7M	-60.56M
Net Income to Company	-30.7M	-60.56M
Net Income - (IS)	-30.7M	-60.56M
Net Income to Common Incl Extra Items	-30.7M	-60.56M
Net Income to Common Excl. Extra Items	-30.7M	-60.56M
Per Share Items
Net EPS - Basic	-13.4	-24.83
Basic EPS - Continuing Operations	-13.4	-24.83
Basic Weighted Average Shares Outstanding	2.29M	2.44M
Net EPS - Diluted	-13.4	-24.83
Diluted EPS - Continuing Operations	-13.4	-24.83
Diluted Weighted Average Shares Outstanding	2.29M	2.44M
Normalized Basic EPS	-8.38	-15.52
Normalized Diluted EPS	-8.38	-15.52
Supplemental Items
EBITDA	-36.05M	-63.58M
EBITA	-36.4M	-64.02M
EBIT	-36.4M	-64.02M
EBITDAR	-32.83M	-62.12M
Normalized Net Income	-19.18M	-37.85M
Supplemental Operating Expense Items
General and Administrative Expenses	4.59M	7.89M
Research And Development Expense From Footnotes	31.81M	56.14M
Net Rental Expense, Total	3.22M	1.46M
Stock-Based Comp., R&D Exp. (Total)	428K	859K
Stock-Based Comp., G&A Exp. (Total)	76K	231K
Total Stock-Based Compensation	504K	1.09M

Fiscal Period: December	2024	2025
Assets
Cash And Equivalents	100M	137M
Total Cash And Short Term Investments	100M	137M
Prepaid Expenses	4.02M	2.14M
Total Current Assets	104M	139M
Gross Property Plant And Equipment	2.54M	22.9M
Accumulated Depreciation	-959K	-1.25M
Net Property Plant And Equipment	1.59M	21.65M
Other Long-Term Assets, Total	1.02M	2.5M
Total Assets	107M	163M
Liabilities
Accounts Payable, Total	849K	2.31M
Accrued Expenses, Total	5.4M	13.16M
Current Portion of Leases	525K	5K
Total Current Liabilities	6.77M	15.48M
Long-Term Leases	-	22.39M
Total Liabilities	6.77M	37.87M
Preferred Stock Convertible	173M	257M
Total Preferred Equity	173M	257M
Common Stock, Total	1K	1K
Additional Paid In Capital	1.59M	3.3M
Retained Earnings	-74.47M	-135M
Total Common Equity	-72.88M	-132M
Total Equity	100M	125M
Total Liabilities And Equity	107M	163M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.29M	2.55M
ECS Total Common Shares Outstanding	2.29M	2.55M
Book Value / Share	-31.82	-51.68
Tangible Book Value	-72.88M	-132M
Tangible Book Value Per Share	-31.82	-51.68
Total Debt	525K	22.4M
Net Debt	-99.62M	-114M
Debt Equivalent Oper. Leases	25.78M	11.7M
Account Code - Inventory Valuation	-	3
Machinery, Total	1.87M	2.62M

Fiscal Period: December	2024	2025
Net Income	-30.7M	-60.56M
Depreciation & Amortization - CF	350K	441K
Depreciation & Amortization, Total	350K	441K
Stock-Based Compensation (CF)	504K	1.09M
Other Operating Activities, Total	697K	1.29M
Change In Accounts Payable	-1.14M	1.46M
Change in Other Net Operating Assets	-1.13M	9.35M
Cash from Operations	-31.42M	-46.92M
Capital Expenditure	-92K	-1.07M
Cash from Investing	-92K	-1.07M
Issuance of Common Stock	420K	589K
Issuance of Preferred Stock	17.14M	83.94M
Cash from Financing	17.56M	84.53M
Net Change in Cash	-13.95M	36.54M
Supplemental Items
Levered Free Cash Flow	-	-28.44M
Unlevered Free Cash Flow	-	-28.44M
Change In Net Working Capital	-	-11.11M

Fiscal Period: December	2024	2025
Profitability
Return on Assets	-	-29.67
Return on Total Capital	-	-32.27
Return On Equity %	-	-53.8
Return on Common Equity	-	59.19
Short Term Liquidity
Current Ratio	15.38	8.97
Quick Ratio	14.79	8.83
Operating Cash Flow to Current Liabilities	-4.64	-3.03
Long Term Solvency
Total Debt/Equity	0.52	17.9
Total Debt / Total Capital	0.52	15.19
LT Debt/Equity	-	17.9
Long-Term Debt / Total Capital	-	15.18
Total Liabilities / Total Assets	6.34	23.24
Total Debt / EBITDA	-0.02	-0.36
Net Debt / EBITDA	3.03	1.84
Total Debt / (EBITDA - Capex)	-0.02	-0.35
Net Debt / (EBITDA - Capex)	3.03	1.81
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	76.37
EBITA, 1 Yr. Growth %	-	75.89
EBIT, 1 Yr. Growth %	-	75.89
Earnings From Cont. Operations, 1 Yr. Growth %	-	97.28
Net Income, 1 Yr. Growth %	-	97.28
Normalized Net Income, 1 Yr. Growth %	-	97.28
Diluted EPS Before Extra, 1 Yr. Growth %	-	85.29
Net Property, Plant and Equip., 1 Yr. Growth %	-	1.26K
Total Assets, 1 Yr. Growth %	-	52.63
Tangible Book Value, 1 Yr. Growth %	-	80.74
Common Equity, 1 Yr. Growth %	-	80.74
Cash From Operations, 1 Yr. Growth %	-	49.37
Capital Expenditures, 1 Yr. Growth %	-	1.06K